Viral Vaccine Market By Vaccine Type (Recombinant, Polysaccharide Vaccines, Live Attenuated Vaccines, Inactivated Vaccines, Subunit Vaccines, mRNA Vaccines, Viral Vector Vaccines, DNA Vaccines, Other), By Disease Indication (Influenza, COVID-19, Hepatitis (A, B, C), Human Papillomavirus (HPV), Measles & Rubella (MMR), Rotavirus, Rabies, Dengue, HIV/AIDS, Others), By Route of Administration (Injectable Vaccines, Oral Vaccines, Intranasal Vaccines), By Manufacturing Technology (Cell-Based Vaccines, Egg-Based Vaccines, Recombinant Technology-Based Vaccines), and By End-user (Hospitals, Specialty Clinics, Government & Public Health Agencies, Homecare Settings), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 – 2035

Table of Contents

1. Methodology & Report Coverage

1.1. Definition & Objective

1.2. Market Evaluation & forecast parameter

1.3. Research Methodology

1.4. Data Validation Sources

1.4.1. Secondary Research

1.4.2. Primary Research

2. Market Overview

3. Viral Vaccine Market: Market Dynamics

3.1. Executive Summary

3.2. Market Driving Factors

3.2.1. Increased awareness of vaccine-preventable diseases drives demand for viral vaccines.

3.2.2. Rising government funding and global vaccination initiatives boost market growth.

3.2.3. Advancements in vaccine technology and research improve efficiency and safety.

3.3. Key industry pitfalls & challenges

3.3.1. High production and development costs limit access in low-income regions.

3.3.2. Vaccine hesitancy and misinformation hinder global adoption and acceptance.

3.3.3. Regulatory hurdles and lengthy approval processes delay market entry.

3.4. Market Opportunities

3.4.1. Expanding demand for vaccines in emerging markets creates significant growth potential.

3.4.2. Innovation in personalized and mRNA vaccine technologies opening new avenues.

3.4.3. Rising focus on preventative healthcare and public health initiatives supports market expansion.

3.5. Porter’s Five Forces Analysis

3.6. PESTLE Analysis

3.7. Regulatory landscape

3.8. Investment Landscape

3.9. ESG Scenario

3.10. Competitive landscape

3.10.1. Company Market Share

3.10.2. Market Positioning

3.10.3. Strategy framework

3.10.4. Recent Acquisitions & Mergers

4. Viral Vaccine Market, Vaccine Type Segment Analysis

4.1. Overview Dynamics

4.1.1. Market Revenue Share, By Vaccine Type, 2025 & 2035

4.1.2. Key Market Trends, Growth Factors, & Opportunities

4.2. Recombinant

4.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.3. Polysaccharide Vaccines

4.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.4. Live Attenuated Vaccines

4.4.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.5. Inactivated Vaccines

4.5.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.6. Subunit Vaccines

4.6.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.7. mRNA Vaccines

4.7.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.8. Viral Vector Vaccines

4.8.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.9. DNA Vaccines

4.9.1. Market Size and Forecast, 2025-2035 (USD Billion)

4.10. Other

4.10.1. Market Size and Forecast, 2025-2035 (USD Billion)

5. Viral Vaccine Market, Disease Segment Analysis

5.1. Overview

5.1.1. Market Revenue Share, By Disease, 2025 & 2035

5.1.2. Key Market Trends, Growth Factors, & Opportunities

5.2. Influenza

5.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

5.3. COVID-19

5.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

5.4. Hepatitis (A, B, C)

5.4.1. Market Size and Forecast, 2025-2035 (USD Billion)

5.5. Human Papillomavirus (HPV)

5.5.1. Market Size and Forecast, 2025-2035 (USD Billion)

5.6. Measles & Rubella (MMR)

5.6.1. Market Size and Forecast, 2025-2035 (USD Billion)

5.7. Rotavirus

5.7.1. Market Size and Forecast, 2025-2035 (USD Billion)

5.8. Rabies

5.8.1. Market Size and Forecast, 2025-2035 (USD Billion)

5.9. Dengue

5.9.1. Market Size and Forecast, 2025-2035 (USD Billion)

5.10. HIV/AIDS

5.10.1. Market Size and Forecast, 2025-2035 (USD Billion)

5.11. Others

5.11.1. Market Size and Forecast, 2025-2035 (USD Billion)

6. Viral Vaccine Market, Route of Administration Segment Analysis

6.1. Overview

6.1.1. Market Revenue Share, By Route of Administration, 2025 & 2035

6.1.2. Key Market Trends, Growth Factors, & Opportunities

6.2. Injectable Vaccines

6.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

6.3. Oral Vaccines

6.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

6.4. Intranasal Vaccines

6.4.1. Market Size and Forecast, 2025-2035 (USD Billion)

7. Viral Vaccine Market, Manufacturing Technology Segment Analysis

7.1. Overview

7.1.1. Market Revenue Share, By Manufacturing Technology, 2025 & 2035

7.1.2. Key Market Trends, Growth Factors, & Opportunities

7.2. Cell-Based Vaccines

7.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

7.3. Egg-Based Vaccines

7.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

7.4. Recombinant Technology-Based Vaccines

7.4.1. Market Size and Forecast, 2025-2035 (USD Billion)

8. Viral Vaccine Market, End-user Segment Analysis

8.1. Overview

8.1.1. Market Revenue Share, By End-user, 2025 & 2035

8.1.2. Key Market Trends, Growth Factors, & Opportunities

8.2. Hospitals

8.2.1. Market Size and Forecast, 2025-2035 (USD Billion)

8.3. Specialty Clinics

8.3.1. Market Size and Forecast, 2025-2035 (USD Billion)

8.4. Government & Public Health Agencies

8.4.1. Market Size and Forecast, 2025-2035 (USD Billion)

8.5. Homecare Settings

8.5.1. Market Size and Forecast, 2025-2035 (USD Billion)

9. Viral Vaccine Market, Region Segment Analysis

9.1. Overview

9.1.1. Global Market Revenue Share, By Region, 2025 & 2035

9.1.2. Global Market Revenue, By Region, 2025-2035 (USD Billion)

9.2. North America

9.2.1. North America Market Revenue, By Country, 2025-2035 (USD Billion)

9.2.2. North America Market Revenue, By Vaccine Type, 2025-2035

9.2.3. North America Market Revenue, By Disease, 2025-2035

9.2.4. North America Market Revenue, By Route of Administration, 2025-2035

9.2.5. North America Market Revenue, By Manufacturing Technology, 2025-2035

9.2.6. North America Market Revenue, By End-user, 2025-2035

9.2.7. The U.S.

9.2.7.1. U.S. Market Revenue, By Vaccine Type, 2025-2035

9.2.7.2. U.S. Market Revenue, By Disease, 2025-2035

9.2.7.3. U.S. Market Revenue, By Route of Administration, 2025-2035

9.2.7.4. U.S. Market Revenue, By Manufacturing Technology, 2025-2035

9.2.7.5. U.S. Market Revenue, By End-user, 2025-2035

9.2.8. Canada

9.2.8.1. Canada Market Revenue, By Vaccine Type, 2025-2035

9.2.8.2. Canada Market Revenue, By Disease, 2025-2035

9.2.8.3. Canada Market Revenue, By Route of Administration, 2025-2035

9.2.8.4. Canada Market Revenue, By Manufacturing Technology, 2025-2035

9.2.8.5. Canada Market Revenue, By End-user, 2025-2035

9.3. Europe

9.3.1. Europe Market Revenue, By Country, 2025-2035 (USD Billion)

9.3.2. Europe Market Revenue, By Vaccine Type, 2025-2035

9.3.3. Europe Market Revenue, By Disease, 2025-2035

9.3.4. Europe Market Revenue, By Route of Administration, 2025-2035

9.3.5. Europe Market Revenue, By Manufacturing Technology, 2025-2035

9.3.6. Europe Market Revenue, By End-user, 2025-2035

9.3.7. Germany

9.3.7.1. Germany Market Revenue, By Vaccine Type, 2025-2035

9.3.7.2. Germany Market Revenue, By Disease, 2025-2035

9.3.7.3. Germany Market Revenue, By Route of Administration, 2025-2035

9.3.7.4. Germany Market Revenue, By Manufacturing Technology, 2025-2035

9.3.7.5. Germany Market Revenue, By End-user, 2025-2035

9.3.8. France

9.3.8.1. France Market Revenue, By Vaccine Type, 2025-2035

9.3.8.2. France Market Revenue, By Disease, 2025-2035

9.3.8.3. France Market Revenue, By Route of Administration, 2025-2035

9.3.8.4. France Market Revenue, By Manufacturing Technology, 2025-2035

9.3.8.5. France Market Revenue, By End-user, 2025-2035

9.3.9. U.K.

9.3.9.1. U.K. Market Revenue, By Vaccine Type, 2025-2035

9.3.9.2. U.K. Market Revenue, By Disease, 2025-2035

9.3.9.3. U.K. Market Revenue, By Route of Administration, 2025-2035

9.3.9.4. U.K. Market Revenue, By Manufacturing Technology, 2025-2035

9.3.9.5. U.K. Market Revenue, By End-user, 2025-2035

9.3.10. Italy

9.3.10.1. Italy Market Revenue, By Vaccine Type, 2025-2035

9.3.10.2. Italy Market Revenue, By Disease, 2025-2035

9.3.10.3. Italy Market Revenue, By Route of Administration, 2025-2035

9.3.10.4. Italy Market Revenue, By Manufacturing Technology, 2025-2035

9.3.10.5. Italy Market Revenue, By End-user, 2025-2035

9.3.11. Spain

9.3.11.1. Spain Market Revenue, By Vaccine Type, 2025-2035

9.3.11.2. Spain Market Revenue, By Disease, 2025-2035

9.3.11.3. Spain Market Revenue, By Route of Administration, 2025-2035

9.3.11.4. Spain Market Revenue, By Manufacturing Technology, 2025-2035

9.3.11.5. Spain Market Revenue, By End-user, 2025-2035

9.3.12. Rest of Europe

9.3.12.1. Rest of Europe Market Revenue, By Vaccine Type, 2025-2035

9.3.12.2. Rest of Europe Market Revenue, By Disease, 2025-2035

9.3.12.3. Rest of Europe Market Revenue, By Route of Administration, 2025-2035

9.3.12.4. Rest of Europe Market Revenue, By Manufacturing Technology, 2025-2035

9.3.12.5. Rest of Europe Market Revenue, By End-user, 2025-2035

9.4. Asia Pacific

9.4.1. Asia Pacific Market Revenue, By Country, 2025-2035 (USD Billion)

9.4.2. Asia Pacific Market Revenue, By Vaccine Type, 2025-2035

9.4.3. Asia Pacific Market Revenue, By Disease, 2025-2035

9.4.4. Asia Pacific Market Revenue, By Route of Administration, 2025-2035

9.4.5. Asia Pacific Market Revenue, By Manufacturing Technology, 2025-2035

9.4.6. Asia Pacific Market Revenue, By End-user, 2025-2035

9.4.7. China

9.4.7.1. China Market Revenue, By Vaccine Type, 2025-2035

9.4.7.2. China Market Revenue, By Disease, 2025-2035

9.4.7.3. China Market Revenue, By Route of Administration, 2025-2035

9.4.7.4. China Market Revenue, By Manufacturing Technology, 2025-2035

9.4.7.5. China Market Revenue, By End-user, 2025-2035

9.4.8. Japan

9.4.8.1. Japan Market Revenue, By Vaccine Type, 2025-2035

9.4.8.2. Japan Market Revenue, By Disease, 2025-2035

9.4.8.3. Japan Market Revenue, By Route of Administration, 2025-2035

9.4.8.4. Japan Market Revenue, By Manufacturing Technology, 2025-2035

9.4.8.5. Japan Market Revenue, By End-user, 2025-2035

9.4.9. India

9.4.9.1. India Market Revenue, By Vaccine Type, 2025-2035

9.4.9.2. India Market Revenue, By Disease, 2025-2035

9.4.9.3. India Market Revenue, By Route of Administration, 2025-2035

9.4.9.4. India Market Revenue, By Manufacturing Technology, 2025-2035

9.4.9.5. India Market Revenue, By End-user, 2025-2035

9.4.10. Australia

9.4.10.1. Australia Market Revenue, By Vaccine Type, 2025-2035

9.4.10.2. Australia Market Revenue, By Disease, 2025-2035

9.4.10.3. Australia Market Revenue, By Route of Administration, 2025-2035

9.4.10.4. Australia Market Revenue, By Manufacturing Technology, 2025-2035

9.4.10.5. Australia Market Revenue, By End-user, 2025-2035

9.4.11. South Korea

9.4.11.1. South Korea Market Revenue, By Vaccine Type, 2025-2035

9.4.11.2. South Korea Market Revenue, By Disease, 2025-2035

9.4.11.3. South Korea Market Revenue, By Route of Administration, 2025-2035

9.4.11.4. South Korea Market Revenue, By Manufacturing Technology, 2025-2035

9.4.11.5. South Korea Market Revenue, By End-user, 2025-2035

9.4.12. Singapore

9.4.12.1. Singapore Market Revenue, By Vaccine Type, 2025-2035

9.4.12.2. Singapore Market Revenue, By Disease, 2025-2035

9.4.12.3. Singapore Market Revenue, By Route of Administration, 2025-2035

9.4.12.4. Singapore Market Revenue, By Manufacturing Technology, 2025-2035

9.4.12.5. Singapore Market Revenue, By End-user, 2025-2035

9.4.13. Rest of Asia Pacific

9.4.13.1. Rest of Asia Pacific Market Revenue, By Vaccine Type, 2025-2035

9.4.13.2. Rest of Asia Pacific Market Revenue, By Disease, 2025-2035

9.4.13.3. Rest of Asia Pacific Market Revenue, By Route of Administration, 2025-2035

9.4.13.4. Rest of Asia Pacific Market Revenue, By Manufacturing Technology, 2025-2035

9.4.13.5. Rest of Asia Pacific Market Revenue, By End-user, 2025-2035

9.5. Latin America

9.5.1. Latin America Market Revenue, By Country, 2025-2035 (USD Billion)

9.5.2. Latin America Market Revenue, By Vaccine Type, 2025-2035

9.5.3. Latin America Market Revenue, By Disease, 2025-2035

9.5.4. Latin America Market Revenue, By Route of Administration, 2025-2035

9.5.5. Latin America Market Revenue, By Manufacturing Technology, 2025-2035

9.5.6. Latin America Market Revenue, By End-user, 2025-2035

9.5.7. Brazil

9.5.7.1. Brazil Market Revenue, By Vaccine Type, 2025-2035

9.5.7.2. Brazil Market Revenue, By Disease, 2025-2035

9.5.7.3. Brazil Market Revenue, By Route of Administration, 2025-2035

9.5.7.4. Brazil Market Revenue, By Manufacturing Technology, 2025-2035

9.5.7.5. Brazil Market Revenue, By End-user, 2025-2035

9.5.8. Argentina

9.5.8.1. Argentina Market Revenue, By Vaccine Type, 2025-2035

9.5.8.2. Argentina Market Revenue, By Disease, 2025-2035

9.5.8.3. Argentina Market Revenue, By Route of Administration, 2025-2035

9.5.8.4. Argentina Market Revenue, By Manufacturing Technology, 2025-2035

9.5.8.5. Argentina Market Revenue, By End-user, 2025-2035

9.5.9. Mexico

9.5.9.1. Mexico Market Revenue, By Vaccine Type, 2025-2035

9.5.9.2. Mexico Market Revenue, By Disease, 2025-2035

9.5.9.3. Mexico Market Revenue, By Route of Administration, 2025-2035

9.5.9.4. Mexico Market Revenue, By Manufacturing Technology, 2025-2035

9.5.9.5. Mexico Market Revenue, By End-user, 2025-2035

9.5.10. Rest of Latin America

9.5.10.1. Rest of Latin America Market Revenue, By Vaccine Type, 2025-2035

9.5.10.2. Rest of Latin America Revenue, By Disease, 2025-2035

9.5.10.3. Rest of Latin America Market Revenue, By Route of Administration, 2025-2035

9.5.10.4. Rest of Latin America Market Revenue, By Manufacturing Technology, 2025-2035

9.5.10.5. Rest of Latin America Market Revenue, By End-user, 2025-2035

9.6. MEA

9.6.1. MEA Market Revenue, By Country, 2025-2035 (USD Billion)

9.6.2. MEA Market Revenue, By Vaccine Type, 2025-2035

9.6.3. MEA Market Revenue, By Disease, 2025-2035

9.6.4. MEA Market Revenue, By Route of Administration, 2025-2035

9.6.5. MEA Market Revenue, By Manufacturing Technology, 2025-2035

9.6.6. MEA Market Revenue, By End-user, 2025-2035

9.6.7. GCC Countries

9.6.7.1. GCC Countries Market Revenue, By Vaccine Type, 2025-2035

9.6.7.2. GCC Countries Market Revenue, By Disease, 2025-2035

9.6.7.3. GCC Countries Market Revenue, By Route of Administration, 2025-2035

9.6.7.4. GCC Countries Market Revenue, By Manufacturing Technology, 2025-2035

9.6.7.5. GCC Countries Market Revenue, By End-user, 2025-2035

9.6.8. South Africa

9.6.8.1. South Africa Market Revenue, By Vaccine Type, 2025-2035

9.6.8.2. South Africa Market Revenue, By Disease, 2025-2035

9.6.8.3. South Africa Market Revenue, By Route of Administration, 2025-2035

9.6.8.4. South Africa Market Revenue, By Manufacturing Technology, 2025-2035

9.6.8.5. South Africa Market Revenue, By End-user, 2025-2035

9.6.9. Rest of Middle-East & Africa

9.6.9.1. Rest of Middle-East & Africa Market Revenue, By Vaccine Type, 2025-2035

9.6.9.2. Rest of Middle-East & Africa Market Revenue, By Disease, 2025-2035

9.6.9.3. Rest of Middle-East & Africa Market Revenue, By Route of Administration, 2025-2035

9.6.9.4. Rest of Middle-East & Africa Market Revenue, By Manufacturing Technology, 2025-2035

9.6.9.5. Rest of Middle-East & Africa Market Revenue, By End-user, 2025-2035

10. Company Profile

10.1. Pfizer Inc.

10.1.1. Business Overview

10.1.2. Financial Performance

10.1.3. Product /Service Offerings

10.1.4. Strategies & recent developments

10.1.5. SWOT Analysis

10.2. Merck & Co., Inc.

10.2.1. Business Overview

10.2.2. Financial Performance

10.2.3. Product /Service Offerings

10.2.4. Strategies & recent developments

10.2.5. SWOT Analysis

10.3. Sanofi S.A.

10.3.1. Business Overview

10.3.2. Financial Performance

10.3.3. Product /Service Offerings

10.3.4. Strategies & recent developments

10.3.5. SWOT Analysis

10.4. GlaxoSmithKline plc (GSK)

10.4.1. Business Overview

10.4.2. Financial Performance

10.4.3. Product /Service Offerings

10.4.4. Strategies & recent developments

10.4.5. SWOT Analysis

10.5. Johnson & Johnson

10.5.1. Business Overview

10.5.2. Financial Performance

10.5.3. Product /Service Offerings

10.5.4. Strategies & recent developments

10.5.5. SWOT Analysis

10.6. AstraZeneca plc

10.6.1. Business Overview

10.6.2. Financial Performance

10.6.3. Product /Service Offerings

10.6.4. Strategies & recent developments

10.6.5. SWOT Analysis

10.7. Moderna, Inc.

10.7.1. Business Overview

10.7.2. Financial Performance

10.7.3. Product /Service Offerings

10.7.4. Strategies & recent developments

10.7.5. SWOT Analysis

10.8. Novartis AG

10.8.1. Business Overview

10.8.2. Financial Performance

10.8.3. Product /Service Offerings

10.8.4. Strategies & recent developments

10.8.5. SWOT Analysis

10.9. Bayer AG

10.9.1. Business Overview

10.9.2. Financial Performance

10.9.3. Product /Service Offerings

10.9.4. Strategies & recent developments

10.9.5. SWOT Analysis

10.10. AbbVie Inc.

10.10.1. Business Overview

10.10.2. Financial Performance

10.10.3. Product /Service Offerings

10.10.4. Strategies & recent developments

10.10.5. SWOT Analysis

10.11. Bristol Myers Squibb Company

10.11.1. Business Overview

10.11.2. Financial Performance

10.11.3. Product /Service Offerings

10.11.4. Strategies & recent developments

10.11.5. SWOT Analysis

10.12. Eli Lilly and Company

10.12.1. Business Overview

10.12.2. Financial Performance

10.12.3. Product /Service Offerings

10.12.4. Strategies & recent developments

10.12.5. SWOT Analysis

10.13. Amgen Inc.

10.13.1. Business Overview

10.13.2. Financial Performance

10.13.3. Product /Service Offerings

10.13.4. Strategies & recent developments

10.13.5. SWOT Analysis

10.14. Gilead Sciences, Inc.

10.14.1. Business Overview

10.14.2. Financial Performance

10.14.3. Product /Service Offerings

10.14.4. Strategies & recent developments

10.14.5. SWOT Analysis

10.15. Regeneron Pharmaceuticals, Inc.

10.15.1. Business Overview

10.15.2. Financial Performance

10.15.3. Product /Service Offerings

10.15.4. Strategies & recent developments

10.15.5. SWOT Analysis

10.16. Takeda Pharmaceutical Company Limited

10.16.1. Business Overview

10.16.2. Financial Performance

10.16.3. Product /Service Offerings

10.16.4. Strategies & recent developments

10.16.5. SWOT Analysis

10.17. Biogen Inc.

10.17.1. Business Overview

10.17.2. Financial Performance

10.17.3. Product /Service Offerings

10.17.4. Strategies & recent developments

10.17.5. SWOT Analysis

10.18. Vertex Pharmaceuticals Incorporated

10.18.1. Business Overview

10.18.2. Financial Performance

10.18.3. Product /Service Offerings

10.18.4. Strategies & recent developments

10.18.5. SWOT Analysis